Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)
6.65USD
20 Apr 2018
$-0.10 (-1.48%)
$6.75
$6.70
$6.80
$6.65
57,572
161,364
$9.85
$5.35
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | $371.63 |
| Shares Outstanding(Mil.): | 50.22 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CRBP.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -0.60 | -- | -- |
| ROI: | -100.08 | 1.58 | 14.38 |
| ROE: | -100.21 | 2.41 | 16.07 |
BRIEF-Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update
* CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE
BRIEF-Corbus Pharmaceuticals Receives $25 Mln Development Award From The Cystic Fibrosis Foundation
* CORBUS PHARMACEUTICALS RECEIVES $25 MILLION DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION TO SUPPORT PHASE 2B CLINICAL STUDY OF LENABASUM Source text for Eikon: Further company coverage:
BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint
* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT
Corbus cystic fibrosis drug to get FDA review on flare-up data
Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.
Corbus cystic fibrosis drug to get U.S. FDA review on flare-up data
Jan 29 Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.
BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln
* CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2EciBBu) Further company coverage:
BRIEF-Corbus Pharma Initiates Phase 2 Study Of Anabasum For Treatment Of Systemic Lupus Erythematosus
* CORBUS PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 STUDY OF ANABASUM FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:
BRIEF-Corbus Pharmaceuticals Q3 loss per share $0.14
* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements
BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study
* Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study
BRIEF-Corbus Pharma prices underwritten public offering of common stock
* Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock
Competitors
| Price | Chg | |
|---|---|---|
| Roche Holding Ltd. (ROG.S) | CHF215.65 | -0.85 |
| Roche Holding Ltd. (RO.S) | CHF220.00 | -0.20 |
| Bristol-Myers Squibb Co (BMY.N) | $51.17 | -0.44 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,306.55 | -- |
| Sanofi SA (SASY.PA) | €65.28 | -0.32 |
| PTC Therapeutics, Inc. (PTCT.OQ) | $26.23 | +0.13 |
| Novartis AG (NOVN.S) | CHF76.08 | -1.20 |
| Bayer AG (BAYGn.DE) | €99.00 | -0.60 |
| Bayer AG (BAYE.F) | -- | -- |
| Galapagos NV (GLPG.AS) | €78.92 | +1.02 |
Estimates